Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 2/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14606255 | 0.79 | CHRNB2 (0.53) | CHRNB2CHRNA4MAPTLTA4HHRH3 | |
| SCHEMBL3361766 | 0.77 | CHRNB2 (0.59) | CHRNB2CHRNA4MAPTLTA4HHRH3 | |
| SCHEMBL26796046 | 0.74 | CHRNB2 (0.49) | CHRNB2CHRNA4MAPTLTA4HHRH3 | |
| SCHEMBL14572016 | 0.74 | CHRNB2 (0.49) | CHRNB2CHRNA4MAPTLTA4HHRH3 | |
| SCHEMBL1640720 | 0.72 | HRH3 (0.59) | LTA4HHRH3KEAP1NFE2L2 | |
| SCHEMBL25903640 | 0.71 | CHRNB2 (0.46) | CHRNB2CHRNA4MAPTLTA4HHRH3 | |
| SCHEMBL14308132 | 0.70 | CHRNB2 (0.62) | CHRNB2CHRNA4LTA4HHRH3KEAP1 | |
| SCHEMBL15360312 | 0.69 | HTR7 (0.50) | CHRNB2CHRNA4LTA4HHRH3KEAP1 | |
| SCHEMBL31388561 | 0.69 | CHRNB2 (0.56) | CHRNB2CHRNA4LTA4HHRH3KEAP1 | |
| SCHEMBL10256425 | 0.69 | CHRNB2 (0.56) | CHRNB2CHRNA4LTA4HHRH3KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239790-A1 | 7-Morpholino-1,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor | LIFEARC (GB) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239790-A1 | 7-Morpholino-1,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor | DCK, ERCC2, POLK | CHRNB2 4539/4885CHRNA4 4772/4885MAPT 4288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.